Covid-19

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna

Moderna Covid-19 vaccine safe and effective in teens

Moderna has announced that its Phase II/III study of its Covid-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of Covid-19 were observed in participants who had received two doses of the Moderna Covid-19… Read More

#Covid-19 #News #Trending News

#Clinical trials #Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Janssen single-dose COVID-19 vaccine approved for use in the UK

Johnson & Johnson has announced topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, demonstrating that the investigational single-dose Covid-19 vaccine in development at Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Royal visit to celebrate key role in vaccine development

Malvern Panalytical, experts in high-precision analytical instruments, welcomed His Royal Highness The Earl of Wessex, Prince Edward, to its Worcestershire headquarters. Malvern Panalytical was selected for the Royal visit, amongst a small number of other Worcestershire businesses, primarily because of its scientific and technical contribution to the development of medicines… Read More

#News #Trending News

#Clinical trial #Covid-19 #Drug development

Covid-19 patients with sepsis one step closer to life-saving treatment

A clinical trial has begun using a human protein called Annexin A5, which is being studied as a potential therapy for Covid-19 patients with sepsis. Annexin A5 is a protein produced inside the human body with unique anti-coagulation (preventing blood clots) and anti-inflammatory properties that could help in the fight… Read More

#News

#Antibodies #Covid-19 #Research

Critically ill Covid-19 patients have normal antibody production

Researchers at Lawson Health Research Institute (Lawson) and Western University have teamed up with local biotech company, Diagnostics Biochem Canada, to better understand Covid-19 and the body’s immune response to the infection. A recently published study followed 28 critically ill patients at London Health Sciences Centre (LHSC); 14 who tested… Read More

#Covid-19 #News

#AstraZeneca #Clinical trials #Covid-19 #Moderna #Pfizer #Research

Behind the UK Cov-Boost trial

The UK government has begun the Cov-Boost clinical trials for a booster coronavirus vaccine in a bid to test its effectiveness against the new variants of the virus. As part of the trial, seven vaccines ordered by the UK government will be tested on thousands of volunteers at random in… Read More

#Covid-19 #Exclusive Content #News

#Covid-19 #Drug delivery #Drug development

EMA issues positive scientific opinion on early treatment of Covid-19

GlaxoSmithKline (GSK) and Vir Biotechnology have announced that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004. This relates to the use of sotrovimab for the treatment of… Read More

#Covid-19 #News

#Clinical research #Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Vaccines

Positive interim Phase II results for GSK Medicago Covid-19 vaccine

Medicago and GlaxoSmithKline (GSK) have reported positive interim Phase II clinical trial safety and immunogenicity data for Medicago’s plant-derived Covid-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant. These results are part of the ongoing Phase II/III study and reiterate the promising profile observed during Phase… Read More

#Covid-19 #News

Patient receiving vaccine
#Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Vaccines

Sanofi and GSK Covid-19 vaccine to progress to Phase III trials

The Sanofi and GSK adjuvanted recombinant Covid-19 vaccine candidate achieved strong rates of neutralising antibody responses, in line with those measured in people who have recovered from Covid-19, in all adult age groups in a Phase II study with 722 volunteers. The Phase II interim results showed 95% to 100%… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #mRNA #Vaccines

CureVac GSK Covid-19 vaccine candidate shows high immunogenicity

CureVac, in collaboration with GSK, has announced that its second-generation Covid-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals. CV2CoV is a co-development between CureVac and GSK and is based on a new mRNA backbone, which differs from… Read More

#Covid-19 #News

Covid-19
#Cancer #Cancer research #Covid-19 #Drug repurposing

Can this cancer drug treat severe cases of Covid-19?

Mount Sinai researchers have found that a widely available and inexpensive drug targeting inflammatory gene has reduced morbidity and mortality in mice infected with SARS-CoV-2. In a study published in Cell, the team reported that the drug, topotecan (TPT), inhibited the expression of inflammatory genes in the lungs of mice… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Research study #Vaccines

Is this the solution to increasing Covid-19 vaccine uptake?

The largest ever study of Covid-19 vaccine messaging shows that emphasising the personal benefits rather than collective of vaccination may be the most effective way to persuade people who are sceptical. Researchers from the University of Oxford, funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre… Read More

#Covid-19 #News #Trending News

#Biopharmaceutical #Covid-19 #Life sciences #Pharmaceutical research #Vaccines

ABPI chief stresses importance of research investment

The Chief Executive of the UK’s Association of the British Pharmaceutical Industry (ABPI), Richard Torbett, has stressed the importance of investment in research in response to the Queen’s Speech delivery. “The response to the pandemic has shown just how critical the UK’s pharmaceutical industry is to our country’s future and… Read More

#News #Trending News

#Clinical trial #Covid-19 #Data

Clinical trials impacted by slow enrolment

The surge in new variants for Covid-19 and an increase in subsequent cases is continuing to have an impact on clinical trials, while still allowing them to resume. The total number of disrupted trials has levelled off, but the number of clinical trials that have resumed continues to rise, although… Read More

#News

#Covid-19 #Drug delivery #Immunology / Virology & Vaccines #Moderna #Vaccines

500 million Covid-19 vaccine doses delivered to lowest income countries

Moderna has announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the Covid-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021. Through this agreement, on behalf of the COVAX Facility, Gavi also retains… Read More

#Covid-19 #News